Genetic Screening for Ehlers-Danlos Syndrome (EDS): A Comprehensive Guide

By ⁠Brandon Colby, MD, Genomics Specialist
Last Updated: February 27, 2025

What is Ehlers-Danlos Syndrome?

Ehlers-Danlos syndrome (EDS) refers to a group of inherited connective tissue disorders that affect collagen, a protein providing strength and elasticity to tissues including skin, joints, blood vessels, and organs. Faulty collagen caused by genetic variants leads to various EDS symptoms.

Common features include:

• Joint hypermobility (flexible joints)
• Stretchy skin that bruises easily
• Tissue fragility
• Chronic pain
• Joint instability and recurrent dislocations
• Cardiovascular issues (in some types)

Early diagnosis through genetic screening aids proper management and prevents complications.

Types of Ehlers-Danlos Syndrome

There are 13 recognized EDS types, each with distinct genetics and clinical features.

1. Hypermobile EDS (hEDS)

• Prevalence: 1 in 3,100 - 5,000
• Genes: Unknown
• Protein: Unknown
• Inheritance: Autosomal Dominant
• Features: Joint hypermobility, instability, chronic pain

2. Classical EDS (cEDS)

• Prevalence: 1 in 20,000 - 40,000
• Genes: COL5A1, COL5A2, COL1A1
• Protein: Type V collagen, Type I collagen
• Inheritance: Autosomal Dominant
• Features: Skin fragility with scars, stretchy velvety skin

3. Vascular EDS (vEDS)

• Prevalence: 1 in 100,000 - 200,000
• Genes: COL3A1, COL1A1
• Protein: Type III collagen, Type I collagen
• Inheritance: Autosomal Dominant
• Features: Arterial and organ fragility, extensive bruising, pneumothorax

4. Periodontal EDS (pEDS)

• Prevalence: <1 in 1,000,000
• Genes: C1R, C1S
• Protein: C1r, C1s
• Inheritance: Autosomal Dominant
• Features: Early gum disease, tooth loss, pretibial plaques

Other rare types include Kyphoscoliotic, Spondylodysplastic, Brittle Cornea Syndrome, Arthrochalasia, Musculocontractural, Classical-like, Dermatosparaxis, Myopathic, and Cardiac-valvular EDS.

Genetics and Inheritance of EDS

Genes provide instructions for proteins. Variants (gene differences) can be harmless or pathogenic (harmful), causing faulty proteins leading to disorders like EDS.

Inheritance Patterns

• Autosomal Dominant: One pathogenic gene variant causes the condition (50% chance of passing to children; affects both genders equally). Types: hEDS, cEDS, vEDS, pEDS.
• Autosomal Recessive: Two pathogenic variants required (both parents must be carriers; each child has a 25% chance). Types: Kyphoscoliotic, Spondylodysplastic, Classical-like.

Genetic Screening for EDS

When to Consider Screening

• Symptoms suggesting EDS
• Family history
• Severe symptoms or complications (arterial rupture, organ fragility)
• Definitive diagnosis needed for management
• Family planning

Types of Screening

• Single Gene Analysis: Specific suspected types (e.g., COL3A1 for vEDS)
• Multi-Gene Panel: Multiple genes tested simultaneously for unclear types
• Whole Exome Sequencing (WES): Comprehensive, used in complex or unresolved cases

Genetic Screening by EDS Type

Hypermobile EDS (hEDS)

No known genetic cause; diagnosed clinically by symptoms.

Classical EDS (cEDS)

90% detectable genetically (COL5A1, COL5A2, rarely COL1A1). Clinical diagnosis still possible if negative.

Vascular EDS (vEDS)

95% detectable genetically (COL3A1, rarely COL1A1). Critical due to life-threatening complications.

Understanding Genetic Screening Results

• Positive Result: Confirms diagnosis, guides management, family testing
• Negative Result: Condition unclear or undetected, especially hEDS
• Variant of Uncertain Significance (VUS): Unknown clinical impact; managed by symptoms, not genetics alone

Benefits of Genetic Screening

• Definitive diagnosis for most types
• Informed medical management and monitoring
• Family planning decisions
• Advances research into treatment

Limitations of Genetic Screening

• No test for hEDS
• Genetic complexity (multiple genes)
• Testing limitations (variant detection)
• Variants of uncertain significance
• Cost and insurance coverage challenges

Frequently Asked Questions

• Genetic screening advised if symptoms, family history, or severe complications exist.
• Consumer tests (23andMe, Ancestry) do not diagnose EDS.
• Negative genetic tests don’t rule out EDS (especially hEDS).
• Rarely, multiple EDS types may coexist.
• Insurance coverage varies; prior authorization may help.

Conclusion

Genetic screening informs diagnosis, management, and family planning for EDS. While screening currently can’t detect hEDS genetics, research continues. Consultation with a knowledgeable provider is crucial.

Additional Resources

• Sequencing.com’s EDS Screening Test
• The Ehlers-Danlos Society
• HEDGE Study
• Ehlers-Danlos National Foundation
• NIH Rare Diseases Information

About The Author

Dr. Brandon Colby MD is a US physician specializing in the personalized prevention of disease through the use of genomic technologies. He’s an expert in genetic testing, genetic analysis, and precision medicine. Dr. Colby is also the Founder of Sequencing.com and the author of Outsmart Your Genes.

Dr. Colby holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University’s Graduate School of Business, and a degree in Genetics with Honors from the University of Michigan. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (⁠⁠ACMG), an Associate of the American College of Preventive Medicine (⁠⁠ACPM), and a member of the National Society of Genetic Counselors (⁠⁠NSGC).